Shares of Fibrocell Science Inc (NASDAQ:FCSC) hit a new 52-week low on Thursday . The company traded as low as $0.60 and last traded at $0.66, with a volume of 67800 shares traded. The stock had previously closed at $0.66.
A number of analysts have weighed in on the company. Zacks Investment Research downgraded Fibrocell Science from a “buy” rating to a “hold” rating in a report on Wednesday, February 14th. HC Wainwright set a $6.00 price target on Fibrocell Science and gave the stock a “buy” rating in a report on Tuesday, January 30th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Fibrocell Science presently has an average rating of “Hold” and a consensus price target of $3.94.
The company has a market cap of $17.35, a P/E ratio of -0.34 and a beta of 0.38.
Several institutional investors and hedge funds have recently modified their holdings of the company. Sabby Management LLC acquired a new stake in shares of Fibrocell Science in the 4th quarter valued at about $733,000. Anson Funds Management LP acquired a new stake in shares of Fibrocell Science in the 4th quarter valued at about $287,000. Armistice Capital LLC acquired a new stake in shares of Fibrocell Science in the 4th quarter valued at about $393,000. Third Security LLC grew its stake in shares of Fibrocell Science by 49.2% in the 4th quarter. Third Security LLC now owns 8,267,413 shares of the company’s stock valued at $5,292,000 after buying an additional 2,727,273 shares during the period. Finally, FNY Partners Fund LP acquired a new stake in shares of Fibrocell Science in the 4th quarter valued at about $129,000. Institutional investors own 40.97% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Fibrocell Science (FCSC) Reaches New 1-Year Low at $0.60” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2018/02/22/fibrocell-science-fcsc-reaches-new-1-year-low-at-0-60.html.
Fibrocell Science Company Profile
Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.
Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.